ABRAXANE meets primary endpoint in phase 3 trial for advanced non-small cell lung cancer

19-Mar-2010 - Australia

An international lung cancer trial has shown positive results in those patients treated with leading breast cancer drug ABRAXANE® in combination with carboplatin. Biopharmaceutical companies Abraxis Bioscience Inc and Specialised Therapeutics Australia Pty Ltd (STA) announced that the extensive trial, at 102 sites globally including Australia, which enrolled 1052 patients suffering advanced non small cell lung cancer (NSCLC), met its primary efficacy endpoint as assessed by an independent radiologist review.

Researchers found those patients treated with ABRAXANE® and carboplatin demonstrated a significant improvement in overall tumour response rate compared with patients treated with a standard chemotherapy formulation containing TAXOL and carboplatin.

The Phase 3 trial was led by principal investigator Mark Socinski, M.D., at the University of North Carolina Lineberger Comprehensive Cancer Center, and is recognised as one of the largest NSCLC clinical studies to be conducted.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance